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Abstract
Background: Genomic and biosocial research data about individuals is rapidly proliferating, bringing the potential for
novel opportunities for data integration and use. The scale, pace and novelty of these applications raise a number of
urgent sociotechnical, ethical and legal questions, including optimal methods of data storage, management and
access. Although the open science movement advocates unfettered access to research data, many of the UK’s
longitudinal cohort studies operate systems of managed data access, in which access is governed by legal and ethical
agreements between stewards of research datasets and researchers wishing to make use of them. Amongst other
things, these agreements aim to respect the reasonable expectations of the research participants who provided data
and samples, as expressed in the consent process. Arguably, responsible data management and governance of data
and sample use are foundational to the consent process in longitudinal studies and are an important source of
trustworthiness in the eyes of those who contribute data to genomic and biosocial research.
Methods: This paper presents an ethnographic case study exploring the foundational principles of a governance
infrastructure for Managing Ethico-social, Technical and Administrative issues in Data ACcess (METADAC), which are
operationalised through a committee known as the METADAC Access Committee. METADAC governs access to
phenotype, genotype and ‘omic’ data and samples from five UK longitudinal studies.
Findings: Using the example of METADAC, we argue that three key structural features are foundational for practising
responsible data sharing: independence and transparency; interdisciplinarity; and participant-centric decision-making.
We observe that the international research community is proactively working towards optimising the use of research
data, integrating/linking these data with routine data generated by health and social care services and other
administrative data services to improve the analysis, interpretation and utility of these data. The governance of these
new complex data assemblages will require a range of expertise from across a number of domains and disciplines,
including that of study participants. Human-mediated decision-making bodies will be central to ensuring achievable,
reasoned and responsible decisions about the use of these data; the METADAC model described in this paper provides
an example of how this could be realised.
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Introduction: managing access to complex and
sensitive research resources
Genomic and biosocial research data about humans con-
tinue to proliferate, bringing with them questions about
who should be able to store, hold and use which data and
samples, for which purposes and with what safeguards.
The research data landscape is changing with new forms
of research data becoming available (e.g. next-generation
sequencing, epigenetic and other ‘omics’ data [1, 2]) and
existing data being increasingly accessible for research (e.
g. via linkage of administrative, environmental or health-
care data to research data [3]). This complexity will only
increase as new informatics technologies that enable
citizen-generated data (e.g. social media, direct-to-
consumer genetic testing and wearable sensors) become
available to combine with research resources in novel ways.
Open science and drivers for data sharing
Expectations surrounding how research data should be
shared are based on international commitments to using,
and re-using, publicly funded research and its outputs for
the public good [4]. Data sharing is also supported by re-
search funding agencies internationally through their pol-
icies on open science (https://www.nwo.nl/en/policies/open
+science/data+management, http://www.allianzinitiative.
de/en/archive/research-data/principles.html, [5–10]). Scien-
tific benefits of data sharing are seen to include verification,
replication and the ability to pool analyses, as well as poten-
tial cost savings [9–13]. Some of the drive for shared data
use comes from patients and publics themselves: already,
many rare disease patients advocate for greater sharing of
genomic and clinical data; the quantified-self movement
promotes and facilitates sharing of data from wearables [14,
15]; citizen scientists demand to access clinical and other
randomised controlled trials data and have filed legal claims
to realise those demands [16]. International policy positions
research data and samples as a public good which can only
be fully realised by their wide and appropriate use [17],
though some types of research data such as that generated
by commercial companies (e.g. pharmaceutical companies)
sit outside this definition. Indeed, some have gone even fur-
ther to argue that not sharing research data is a breach of
participant, patient and public rights and is itself a harm
[18]. While the open science movement advocates unfet-
tered access to research practices and the data produced by
them, when those data are individual-level human data, ac-
cess and re-use must be managed within relevant legal and
ethical requirements, taking account of specific agreements
together with the reasonable expectations of the research
participants who provided those data and samples. These
requirements, agreements and expectations are embodied
in the consents that study participants, or their guardians if
they are minors, give at the outset of the study and, often,
for new collections or sub-studies.
Data sharing, longitudinal studies and the consent
process
To date, the majority of genomic and biosocial research
data made available for sharing in the UK have been de-
rived originally from publicly funded research studies:
longitudinal studies [19–21] (e.g. birth cohorts, house-
hold panel studies, other population and disease-based
biobanks, clinical trials); survey and other social science
datasets; and case-control studies, including case series
collected/generated for research purposes and typically
compared to a research-generated control group (e.g.
Wellcome Trust Case Control Consortium [22]).
In longitudinal studies, the focus of this paper, it is not
possible to foresee all possible research uses at the out-
set of a study. Data and samples may be used for long
after their collection, sometimes decades afterwards. For
studies whose raison d’etre is the provision of a scientific
resource for which public good is the intended outcome
and impact, renewed consent for each and every new
research use would not only be unwieldy but would
impede that aim. Instead, broad consent (within specific
stipulations reflecting contemporary social values and
scientific practice) are sought for future uses of the data
and samples collected. In the UK, under the Human
Tissue Act 2004 (https://www.legislation.gov.uk/ukpga/
2004/30/contents) and Health Research Authority, the
principles and contents of information given to study
participants in consent and participant information
documentation for different forms of data and samples
are prescribed [23, 24].
But consent is a process, one which does not finish
with the receipt of information and the signing of a
form. Ethical approval for studies using broad consent
includes mechanisms to ensure that those consents are
respected and the expectations inherent in them are
maintained, for example, explicitly stating which bodies
can approve data and sample access. Appropriate, respon-
sible data management and governance of the uses of
those data and samples are foundational to this ongoing
consent process in longitudinal studies and an important
source of their trustworthiness in the eyes of individuals
who have contributed data and continue to permit its
storage and use. While trust is crucial for ensuring public
support for research generally, for longitudinal studies, this
requirement is particularly acute as ongoing research par-
ticipation is vital to the longevity, productivity and impact
of those studies. Research participants quite reasonably
expect that their privacy (including confidentiality) will be
protected and that uses of the data and samples they con-
tribute will fall within agreed and anticipated parameters.
Data Access Committees
While Research Ethics Committees (RECs, also called In-
stitutional Review Boards or Research Ethics Boards)
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interpret the ethical, legal and social frameworks within
which studies are conducted and determine how data and
samples may be used, data access permissions in the UK
are governed by a hierarchy of regulatory processes and
bodies depending on the data’s sensitivity and potential
disclosivity (the ease and precision with which individuals
may be identified). Light-touch administrative processes
manage low-dimensional data with a low risk of disclosure
or other participant harms. Data Access Committees
(DACs) manage more complex or higher-risk data access.
Key assessment criteria for determining the release—and
access route—of such data include (1) consistency with
original ethical approval, including consents and informa-
tion materials and the stated aim of the data collection,
and the risk of identification of individual participants; (2)
issues that may directly concern individual participants,
such as the risk of identifying a previously unknown dis-
ease or strong disease determinant which may warrant
clinical action, or the risk of bringing a long-standing
study into disrepute; (3) unreasonably damaging the intel-
lectual property of the project, or otherwise undermining
the effort invested by its investigators or data custodians
(often more than one generation of researchers).
DACs may consider any risks which may impact the
individual participant or otherwise breach their expecta-
tions, thereby provoking them to withdraw from a study.
In addition to the above criteria, some DACs assess the
quality of the science or potential public benefit for all
applications, and nearly all committees assess the quality
and potential benefit of the science when there is a re-
quest for use of a finite resource (e.g. blood samples).
Across the research/scientific community in the gen-
omic, health and social sciences, there is a strong con-
sensus that the application of all such criteria (when
applied in a proportionate and transparent manner) is
good for society and ‘good for science’ [25].
Data access governance in the UK
In the UK, access to data and samples—the ‘resources’ of
longitudinal and other research studies—is operationalised
by a networked series of independent data repositories and
independent data governance infrastructures, though some
longitudinal studies successfully operate in-house or par-
tially in-house governance and data issue mechanisms.
Governance of access permissions (ethics and policy over-
sight) and governance of data issue (technical governance)
may be managed jointly or by separate infrastructures. Each
of these governance infrastructures is designed to ethically,
legally, efficiently and securely manage access (permissions
and/or distribution) to research resources of varied levels of
complexity and sensitivity. For many UK longitudinal stud-
ies, data can be accessed online by bona fide researchers
and are governed by end-user licences. Access decisions
may also be made based on algorithms and straightforward
rules for legitimate access. These are generally rapid mecha-
nisms for access, notwithstanding any additional time re-
quired for online training upon registration to a data
repository (e.g. UKDA training in data management [24])
or additional administrative processes for managing cost re-
covery. The data released by these mechanisms are those
for which there is deemed to be a low risk of individual dis-
closure and which are considered not to raise additional
ethical issues. Some data will only ever be made available in
secure privacy-protected settings—where researchers travel
to the data location (e.g. secure air-gapped data centres) or
send the analysis to the data (e.g. DataSHIELD) and receive
back only the analytical outcomes [26]. Use of finite re-
sources such as blood, urine or other biological samples will
always require additional oversight for legal (e.g. Human
Tissue Act 2004 requirements), ethical and scientific rea-
sons and because each use of samples necessarily precludes
future uses of those samples and therefore must be judged
more carefully.
Classes of research data which are potentially sensitive,
insofar as they are disclosive and/or raise particular ethical
concerns (e.g. incidental/secondary findings), require add-
itional access oversight. Beyond the character of the data
themselves, some research uses of data are also potentially
controversial and may thereby raise ethical issues and po-
tential harms for research participants themselves, or for
the longitudinal studies of which they are a part. Some
types of research are particularly likely to raise issues of po-
tential participant and/or study harms, e.g. those involving
potentially stigmatising issues, such as mental health, sexu-
ality, criminality and certain diseases, or those in which re-
searchers are perceived to make a commercial gain.
Particular forms of or combinations of data also raise risks
of disclosure. That individuals can be identified within a
genetic dataset has been demonstrated methodologically
[27, 28], but only where there is a reference sample/se-
quence available [29]. For most practical applications iden-
tification is unlikely, though this may change with
increasing availability of commercial genotyping. Identifica-
tion of individuals via phenotype data, though less certain
than genetic identification, is easier to enact if large num-
bers or certain classes of variables are combined in analyses
(e.g. place of residence if defined too narrowly, minority
ethnicity, disability, rare disease status) or, as in longitudinal
studies, repeated measures are available. Research questions
which further combine genotypic and phenotypic data and/
or samples may increase the potential for disclosure of indi-
vidual identity. Whether the important issue for disclosure
is one of identifying the individual per se (i.e. that a particu-
lar individual belongs to a longitudinal study) or whether it
is about identifying the individual and information about
them is an empirical question that requires further examin-
ation. Where there are higher risks of disclosure or the
proposed research raises other potential harms, online
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registration and end-user licencing are not sufficient safe-
guards. Decisions about complex societal values are ultim-
ately not amenable to a simple algorithmic approach
whether derived heuristically or, for example, via machine
learning. We argue that a human-mediated review and
decision-making process are then required. Moreover, we
argue that study participants must be central to this
decision-making, seeing through to its conclusion the on-
going consent dialogue initiated in consent and participant
information, procedures and documents.
Methods
In this paper, we present an ethnographic case study [30]
exploring the foundational principles of one infrastructure
for Managing Ethico-social, Technical and Administrative
issues in Data ACcess (METADAC), i.e. the ethics and pol-
icy oversight of data access. The METADAC infrastructure
(that is, the METADAC Access Committee and associated
work of the pilot project described below) aims to put into
practice the tenets of responsible data sharing [31, 32] and,
in particular, operationalises incorporation of study partici-
pant voices and perspectives in access decision-making.
The case study approach allows an in-depth consideration
of a particular instance of practice, or ‘case’. As Stake [33]
describes, the case study is ‘the study of the particularity
and complexity of a single case, coming to understand its
activity within important circumstances’ (p. 6). Case studies
may involve a range of methods, the prime criteria being
those most able to elicit in-depth, rather than summary,
understandings of the object of study; in this case qualita-
tive methods. The analysis in this case study here was in-
formed by a qualitative ethnographic evaluation study
conducted alongside the METADAC pilot. The ethno-
graphic evaluation included observations of METADAC
committee meetings (n = 16) and policy development work-
shops (n = 4) from June 2016 to October 2017. Meetings
were observed by JTM. Twenty-seven interviews were con-
ducted by JTM from March to August 2017 with 18 in-
ternal METADAC stakeholders (committee members,
funders, study representations, technical review team mem-
bers) and 9 METADAC applicants (from 31 invitations). In-
ternal stakeholders were asked about METADAC processes
and policies. Applicants were asked about their experience
of the application process. Meeting observations and inter-
view transcripts were coded thematically using the constant
comparative approach [34] and following the steps pro-
vided by Braun and Clarke [35] for organising analysis with-
out the imposition of a specific epistemic framework. This
approach involves researchers familiarising themselves with
the data corpus (e.g. the interview data in this study), gener-
ating initial codes and then developing, reviewing and de-
fining themes. Having identified our themes using this
approach, we took a constructivist-interpretivist approach
to interpret the themes, i.e. ‘particular actors, in particular
places, at particular times, fashion meaning out of events
and phenomena through prolonged, complex processes of
social interaction involving history, language and action’
and ‘that to understand this world of meaning one must in-
terpret it’ [36]. We present this analysis with representative
extracts from the interviews and description derived from
the observational notes of the meetings.
Results: the METADAC infrastructure
The METADAC infrastructure hosts a Data Access Com-
mittee (the METADAC Access Committee) governing
access to the complex and sensitive genotypic and pheno-
typic classes of data and biological samples (see Table 1)
generated by five longitudinal studies in the UK [37]: the
National Child Development Study (a.k.a. 1958 Birth Co-
hort) [38], 1970 Birth Cohort Study (BCS70) [39], English
Longitudinal Study of Ageing (ELSA) [40], Millennium
Study [41] and Understanding Society (UK Household
Longitudinal study) [42, 43]. It also acts as an appeals
committee to one other longitudinal study (TwinsUK).
METADAC has become the UK’s only independent,
multi-study data and sample access infrastructure for lon-
gitudinal studies. The 3-year METADAC pilot brought to-
gether, under one infrastructure, a number of separate
data and sample access structures. Meetings to review ap-
plications are held at six-weekly intervals, primarily as
teleconferences and twice annually through face-to-face
meetings, when other planning and policy development
workshops also occur. Administratively, the METADAC
Secretariat manages logs and performs a quality audit of
all incoming applications. The Secretariat serves as the
hub for all METADAC communication and interactions
with and between stakeholders. Three key structural
features provide the foundation for practising responsible
data sharing: independence and transparency; interdisci-
plinarity; and participant-centric decision-making. These
features are realised in the access assessment criteria by
which the METADAC Access Committee makes its
decisions (see Table 2).
Independence and transparency
One way of safeguarding the right to privacy and the right
to benefit from science is to ensure a robust and independ-
ent data access process, especially for the most complex
and sensitive research resources. The METADAC process
has promoted fair, consistent and transparent practices of
data access, including making these openly available on its
website. An independent mechanism for access, particularly
for more complex and sensitive data and sample access,
supports these processes. The importance of independence
is recognised by funders, for example, Wellcome’s recent
Longitudinal Population Studies Strategy [8], and reflected
in its criteria for funding longitudinal studies:
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If it is not possible to fully inform participants about
how their data could be used, it is essential that
robust governance is in place, for example, ensuring
there is an independent, accountable decision-making
body that can provide assurances that data are being
used and linked appropriately and responsibly. (p.6).
Four additional benefits of independent, multi-study
access processes are clear and go beyond the values and
norms of fair, transparent and ethical practice. First, in
the competitive academic environment in which most
researchers work, data ‘hugging’ or hoarding—real or
perceived—by researchers internal to a study can result
in constraints on sharing [44–46]. Independent access
processes, be they via registered access [47] or DACs,
support data accessibility. Second, study-independent,
multi-study access bodies can facilitate data discovery.
Year-on-year increases in applications and approvals
through METADAC (a 2.5-fold increase over the first
24 months of operation) are a testament to the increas-
ing international interest in the use of UK longitudinal
Table 1 Classes of data and their access regulation
Data type and sensitivity Data available
from
Governance Data distribution
Class 1 Low risk survey/phenotype-only data, e.g.
social, economic, psychological and health
data.
UK Data
Archive
Requires registered access—online (clickable)
end-user licences.
Data is distributed by the
UK Data Archive.
Class 2 Low sensitivity genetic-only data, e.g. genome-
wide single nucleotide polymorphism [SNP]
data generated from a standard chip with no
phenotype information except gender and a
coarse measure of area of residence.
European
Genome-
phenome
Archive (EGA)
Requires application to the Sanger DAC,
administrative decision based on algorithm of
criteria for access.
Data are distributed by
the EGA.
Class 3 Potentially disclosive survey/phenotype-only
data, e.g. small geographic area. Requires
application to a study-based Data Access Com-
mittee made up of study investigators and
study technical staff.
Study DAC Data may be issued on special licence or may
be accessible only in on or off-site data safe
havens.
Data is distributed, or the
data safe haven hosted,
by the study.
Class 4 New forms of genetic-only data, e.g. exome se-
quence and epigenetic data, are reviewed by
METADAC until their ethical implication/sensi-
tivity is established.
METADAC Application requires review and approval from
the METADAC Access Committee. Application
includes signed agreement to conditions of
use. Data use is monitored annually.
Data are distributed by
the EGA.
Class 5 Genetic-only data with known ethical issues,
e.g. incidental findings risk in exome data.
METADAC Application requires review and approval from
the METADAC Access Committee. Application
includes signed agreement to conditions of
use. Data use is monitored annually.
Data are distributed by
the EGA.
Class 6 Biological samples. Use of biological samples
will always require additional oversight for
ethical and scientific reasons.
METADAC Application requires independent scientific
review and approval from the METADAC
Access Committee.
Samples are issued by the
relevant study under
Material Transfer
Agreements.
Class 7 Any combination of Classes 1 to 6, e.g.
individual-level phenotype data linked to geno-
type data or samples, is potentially more disclo-
sive than any one class of data alone.
METADAC Application requires review and approval from
the METADAC Access Committee. Application
includes signed agreement to conditions of
use. Data use is monitored annually.
Combined datasets are
issued on unique IDs and
distributed by the study
and EGA.
Class 8 Non-research data. High risk when multiple
variables are combined.
Various Certain administrative datasets, e.g.
education and criminal records, are available
for research via the Administrative Data
Research Network. Individual-level health data
is available for research via NHS Digital).
Various
Table 2: METADAC assessment criteria
1. The application has been submitted by bona fide researchers (using
the MRC definition [21]).
2. The application does not risk producing information that may allow
individual study participants to be identified.
3. The application does not violate (or potentially violate) any of the
ethical permissions granted to the study and/or any of the consent
forms signed by the participants or their guardians.
4. The application addresses topics that fall within the acknowledged
remit of the project, as understood by participants.
5. There is no significant risk that the application might upset or
alienate study members or of reducing their willingness to
continue as active participants.
6. There is no significant risk that the application might harm
individuals in the study, or the study as a whole.
7. The application does not require access to a depletable finite
resource (whole blood extracted DNA, blood, saliva and urine).
OR The quality of the science has been reviewed formally by
independent external reviewers (agreed by METADAC) and has
been judged to merit the use of finite biological samples. NB:
Applications for finite bio-samples are seen as being in competition
with other potential future uses of those samples, and therefore the
quality of the science is reviewed formally.
8. Includes a high quality plain language summary—following
METADAC guidance.
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studies and demonstrate the role of METADAC in enab-
ling access to study resources. Moreover, researchers ap-
plying to METADAC are signposted to other similar
studies and are able to make data and/or sample access
applications to multiple studies simultaneously. Third,
an independent committee allows determinations to be
made about new uses of data and samples out-with the
natural tendency of studies to be risk-averse regarding
their own resource. As users of the resources return de-
rived datasets and code for variable creation, rapid as-
sessment of the ethical/governance implications of the
uses and governance of new forms of data (e.g. exome
sequencing and epigenetic data) is actioned, and the pa-
rameters for onward use are established through consen-
sus. But of course, independent does not mean detached.
Having representatives from the studies at the table is
vital and enables the Access Committee to ensure that
the particularities of the study are taken into account
and that their future uses are optimised. METADAC has
a responsibility to the ongoing ‘health and wellbeing’ of
the studies and their participants and not simply to fa-
cilitate the exploitation of their data and samples.
Fourth, METADAC enables learning across the studies
under its remit, sharing good practice but also providing
leverage to change practice. For example, one of the
studies under METADAC governance, Understanding
Society (the UK Household Longitudinal study), has
been able to extend the availability of its genetic data
resource internationally. The governance of multiple
studies made it evident that Understanding Society’s
historical restrictions on international access to its data
were not a fundamental feature of longitudinal studies in
the UK—other studies had no such restrictions. The exist-
ence of international access practices in the other studies
under METADAC enabled the study directors to reassure
their stakeholders that extending their access practices to
harmonise with those of others was safe, proportionate
and ethically acceptable. In short, there has been a virtu-
ous circle of learning amongst METADAC studies.
Interdisciplinarity
Because no individual or group can possibly hold know-
ledge of all aspects of research, research ethics and gov-
ernance [48], the METADAC Access Committee is
comprised of committee members with social, biomedical,
ethical, legal and clinical expertise and individuals with
study-facing expertise. Committee meetings also include,
as observers, study PIs or study representatives, funder
representatives and members of the Technical Review
Team (TRT) who support the decision-making. The
METADAC Secretariat and the ethnographic observer
(JTM) also attend meetings. Where appropriate, the com-
mittee also takes advantage of third-party specialist know-
ledge, particularly where an applicant seeks to use finite
samples. The METADAC Access Committee is chaired by
a social scientist with ethics expertise (MJM), and its dep-
uty chair (NW) has bioscience and bioinformatics expert-
ise. The TRT is chaired (PRB) by a biomedical scientist
with data science expertise.
The ethnographic study demonstrated that each of the
contributors to the METADAC Committee brings par-
ticular understandings and perspectives which contrib-
ute richness to collaborative decision-making but that
these are understandings that are not rigidly bound, with
many members contributing across these domains.
Study-facing committee members, currently two mem-
bers of longitudinal studies not governed by METADAC,
bring (i) embedded and embodied subjective experience of
longitudinal studies and thereby of study participants’ rea-
sonable expectations, and (ii) insights into the project pro-
posals that are not coloured by specialist knowledge of the
same field. While researchers may be carried along by the
importance and interest of a particular exploration (it an-
swers an interesting research question), study-facing mem-
bers are more likely to see each application ‘anew’ and spot
where concerns may be raised for participants. We elabor-
ate this contribution further below.
Committee members with legal and ethical expertise
bring (i) knowledge of relevant laws and regulation (par-
ticularly data protection law, access, consent and issues
around data privacy and biomedical research); (ii) under-
standing of the ethical norms, values and principles
underpinning decision-making and their implications for
protecting and promoting the rights, interests and wel-
fare of participants, researchers and the broader commu-
nity; and (iii) awareness of the remit and purpose of
DACs as well as ensuring the clarity and transparency of
METADAC practices and the documentation which
seeks to explain them.
Biomedical scientists bring (i) an awareness of meth-
odology, used not to judge the science but instead to
understand whether variables requested are ‘necessary
and reasonable’; (ii) understanding of the biomedical
background to research, to judge the likely potential for
incidental or secondary findings in research which at
first glance may not raise clinically actionable findings;
and (iii) awareness of related published material or simi-
lar data resources that may assist applicants in carrying
out research.
Social scientists bring (i) methodological expertise to as-
sess the aims, feasibility and study designs being proposed;
(ii) understanding of social and environmental contexts
when and where data were collected and their potential im-
pact; (iii) awareness of issues that may give rise to ethical or
public concern, often reframing scientific descriptions which
uncover simplistic or paternalistic assumptions which may
trigger participant concerns; and (iv) experience of working
with other epidemiological and longitudinal studies.
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Clinicians bring understanding of (i) both the serious-
ness and treatability of genetically influenced illnesses;
(ii) the sometimes blurred boundaries between research
and clinical practice, highlighting the complexities and
impact of communicating uncertainties to patients and
their families, especially in the contexts of interpreting
genetic variants and reporting unlooked for findings;
and (iii) a working appreciation of negotiating meaning-
ful informed consent to genetic testing with patients
when results may not be predicted or imminent.
The TRT provides practical insight on the affordances
of the studies and a broad evaluation of disclosure risk
and incidental finding risk, based on a knowledge of the
size of the dataset, prevalence and heritability of the
condition and issues that will require further detailed
discussion in committee. The TRT includes individuals
with expertise about the study data and other resources.
They offer the Access Committee insight into what data
resources are available, the format and affordances of
those resources and, for example, whether there are spe-
cific technical or other restrictions on their use.
Study PIs/representatives bring a strong awareness of
the field generally and their own studies in particular; the
availability and relevance of data, any weaknesses in the
data (e.g. a low response rate in a particular questionnaire)
and other relevant data not known to the applicant—
whether from a new wave or from another longitudinal
study with similar data. Similarly, funders contribute un-
derstanding of strategic and policy direction nationally
and internationally. In practice, any member may bring a
contribution from many of these types.
This rich mix of participants brings to bear
perspectives and understandings which support inde-
pendent and transparent decision-making. During the
ethnographic evaluation that has run in parallel to the
formation of METADAC, internal stakeholders have fre-
quently highlighted the value of having a range of discip-
linary expertise in the Access Committee:
A multi-disciplinary approach is really vital so that we
have both the technical expertise, ethical expertise,
social sciences expertise, so that all those elements
can be brought to one place to determine what is the
optimal approach. (from evaluation interview with
METADAC Committee member)
If there are ethical issues, there is someone who is a
specialist in that and who’s thinking about it and
brings issues up if they need to be discussed …there
are lots of different people on [METADAC] from lots
of different backgrounds and disciplines ... So there
are different people thinking about these things.
(from evaluation interview with METADAC Technical
Review Team member)
In the ethnographic evaluation, the diversity of the
committee was seen to produce higher quality reflection
and analysis on matters of concern [49]. Participants de-
scribed that hearing perspectives from other fields im-
proved their own critical thinking. But, as Fitzgerald and
Callard [50] put it: ‘There are two current certainties in
… interdisciplinary research: everyone wants to do it,
and no one quite knows how’ (p.23). While the benefits
of multi-, inter- or transdisciplinary working in data gov-
ernance are still emerging and deserve careful documen-
tation, for METADAC, there appears to be some clear
benefits, particularly in supporting a rounded approach
that takes account of a plurality of perspectives in com-
ing to consensual decisions. That is not to suggest that
consensus is necessarily or always straightforward; it re-
quires work. It is not simply multiple perspectives from
distinct disciplines that are brought to bear in decision-
making (not least because some members already span
disciplines), but also multiple standpoints or subject po-
sitions [51, 52]; more colloquially, we say people ‘wear
many hats’. Individuals taking part in METADAC
decision-making inhabit and draw upon multiple subject
positions: researcher/researched, data custodian/data
producer, etc. We argue that it is these multiple subject
positions which are important in decision-making pre-
cisely because they call upon the different interests,
commitments and expectations which are central to en-
suring decisions made about data and sample access are
coherent with, and respect the contributions made by,
study participants.
Discussion: participant-centred decision-making
Engaging the perspectives of stakeholder communities
within research and involving them in decision making are
lauded for meeting ethical expectations and norms as well
as for its (potential) pragmatic outcomes, improving the
alignment of research with societal values and the relevance
of research outputs or their translation [48]. Engagement is
variously understood as a form of democracy, an act of re-
spect and an acknowledgement of human rights [53–59].
In Braidotti’s vision of affirmative ethics [60, 61], the under-
standing that ‘we are all in this together’ even if we are ‘not
one and the same’ [62] places upon science an injunction
to work with the communities, public and research partici-
pants who are both the basis and beneficiaries of science.
Of course, study participants are already at the centre of
longitudinal studies; it is only with their permission and
with their contributions of data and samples that the stud-
ies endure. Respecting those contributions means that
participant-centredness must do more than simply consider
them research subjects. Engaging study participants in
meaningful decision-making is both an ethical and practical
solution, enabling alignment with participant expectations,
social norms and values and, arguably, improving study
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outputs as a result. As we argue elsewhere, engagement
brings study participants closer to the research but also
brings the research and researchers closer to them [48]. In
the case of longitudinal studies, there is a long history of
study participant involvement in decision-making. The
Avon Longitudinal Study of Parents and Children
(ALSPAC) has an advisory panel comprised of study partic-
ipants and has included on its ethics committee original co-
hort participants (now nearing 26 years of age) for the past
decade and parent members for much longer [63].
ALSPAC study participant members now number half of
the ethics committee and their involvement in ethical
decision-making is normalised and embedded. In META-
DAC, the need for multiple perspectives, met through the
interdisciplinary constitution of its Access Committee,
demands the inclusion of study-facing participants. By
incorporating study-facing members, METADAC was seen
by members and observers of the committee as contribut-
ing new and valuable voices to discussions about data ac-
cess and use and expanding how Data Access Committees
have historically functioned:
They’re the ones who have insights, that nobody else
has, on the anxieties, the concerns, the hopes about
how their data will be used, so they absolutely need to
be represented. (from evaluation interview with
METADAC Committee member)
Participant-centredness can, of course, take many
forms: it can be agonistic or it can be solidaristic; it can
be prescribed or it can be negotiated [64]. In scientific
contexts, participatory activities can range from unidir-
ectional communication and outreach, through various
levels of involvement in decision-making, to participant
control, as in citizen science endeavours. Each has ad-
vantages and limitations. In METADAC, which requires
understanding and expertise from many perspectives in
order to make responsible decisions, participant-
centredness takes three forms: (1) respecting study par-
ticipant expectations, (2) involving study participants in
decision-making roles and (3) communicating the results
of access decisions to participants (and others) in a for-
mat that is clear and accessible, for example, in plain
language summaries.
Study participant expectations
Participant expectations of longitudinal research are cen-
tral to METADAC’s access decisions. Criterion 5 (Table 2)
seeks to ensure that there is no significant risk of upsetting
or alienating participants. While this is an instrumental
value, in that it seeks to reduce loss to a study or studies,
it is also primarily a value-based position aimed at respect-
ing the participation and on-going commitment of study
participants. Though in a cognate context, Caldicott’s
injunction that participants (in her report, patients) should
not be ‘surprised’ by the uses of their data and samples
also holds true for METADAC. Assessment criterion 5
(Table 2) is called upon in METADAC Access Committee
meetings in the form of two questions: (1) Would the re-
search proposed by an applicant be likely to upset or
alienate participants? and (2) Would the research breach
the reasonable expectations of participants? It is via these
questions that issues of potential sensitivity and contro-
versy may be addressed. It might be plausible to construct
an algorithm to identify certain classes of research as sen-
sitive, and indeed for one of the studies under METADAC
oversight, there is a specific list of research topics and
types which are restricted. Specifically, the 1958 Birth
Cohort explicitly restricts studies of the genetics of
intelligence, sexuality and criminality. This stipulation is
based on information provided to nurses during their for-
mal training for taking samples from study participants.
While not included in the information material given to
study participants during consent, which are always the
foundation of legitimate access requests, a previous com-
mittee determined that nurses might reasonably have been
expected to communicate those exceptions to at least
some study participants, and therefore, these continue to
be respected. A list of restricted variables has been identi-
fied, but decisions about how and whether the research
purposes proposed for their use are acceptable and ap-
proval granted are often more complicated than simple
yes/no determinations. A level of interpretation and
judgement is necessary, one which requires human
decision-making.
Study participant involvement in decision-making
An ethnographic (observational) study of a predecessor to
the METADAC Committee identified, during access deci-
sions, repeated consideration of what the participant or
public might ‘think’ of a particular application for data use
[44]. In that DAC, however, understanding of participant’s
voice was hypothetical only, because no participants or
other study-facing members were involved in DAC
decision-making and no empirical account of their views
was available (e.g. in qualitative studies of their expecta-
tions of involvement). The METADAC infrastructure
addresses this absence by including two study-facing
members who are themselves participants of longitudinal
studies. To avoid conflicts of interest, these study-facing
members are independent of the studies for which META-
DAC provides oversight. This decision was taken to avoid
the assumption that study-facing members directly repre-
sent the study population. While two committee members
cannot feasibly represent the individual interests of tens of
thousands of study participants, the aim is to ensure that
the embodied, material and emotional experience of being
a study participant is incorporated into data governance
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decision-making. In this pilot phase of METADAC, devel-
opment of study-facing members’ involvement is assisted
by involving individual study participants who also happen
to have active research careers in the social sciences.
METADAC has avoided treating study-facing mem-
bers’ views as ‘non-expert’. Involvement of study partici-
pants in decision-making roles requires active work to
ensure it is meaningful; a learning process that means
that the contributions of these study participant mem-
bers deepen as their knowledge and understanding of
governance issues grow. Pre-meetings are held with all
new members of the METADAC, whatever their back-
ground, and continue for study-facing members as often
as they wish, to create a space for longer discussion of
applications and other issues that is typically available in
a 90-min committee meeting. After each committee
meeting, informal debrief sessions are hosted to make
sure that any uncertainties are resolved, wider observa-
tions can be aired and suggestions made. Active chairing
in committee meetings and an inclusive culture facili-
tates all committee members to express their positions.
The Secretariat acts as the first point of call when re-
solving practical problems, and the Access Committee
as a whole can be used to develop insights into particu-
lar areas of procedure or policy.
Even within the acknowledged limitations above, deci-
sions made with study-facing members create different
outcomes to those made without their insight and ex-
perience. For example, the embodied sense of discomfort
or unease from the participant perspective (or indeed
from other members) warrants greater scrutiny of appli-
cations by the Access Committee and can and does en-
courage different decisions to be made. Some areas of
sensitivity are not easily exposed through schematic,
algorithmic or technical evaluation. We call upon study-
facing members to scrutinise areas of uncertainty, along
with other members, to articulate a range of potential
study participants’ responses in order to highlight poten-
tial risks and harms of any given application and to an-
ticipate how even well-intentioned research outcomes
can produce harms, including those caused by sensatio-
nalised media reactions. Some of this reasoning can be
messy and speculative; it stays with the troubling or
unforeseen parts of an application and tries to consider
how the expectations of science may align with or com-
promise those of study participants. In this regard,
study-facing members bring a unique perspective and
position to the committee. But they do more than this.
In the METADAC, the study-facing members have been
central in developing policy, particularly as new forms of
data become available. Deep and often lively discussions
during METADAC development workshops become the
basis of policy and processes (e.g. recent access policy
developed for exome sequence data and epigenetic data).
In this way, decision-making in METADAC occurs with
study participants as part of an ongoing, collaborative
and negotiated process.
Plain language summaries
Although plain language summaries (PLSs), or ‘lay sum-
maries’, are an expectation of communication of much
research—and most funders now require these for their
applications—researchers often do not communicate
their work in ways which are clear or accessible to non-
expert audiences. METADAC owes a duty to communi-
cate the outputs of their contributions to the partici-
pants of those studies for which it provides oversight
and to their funders. PLSs are published on the META-
DAC website [1]. Development of PLS policy, processes
and guidance, therefore, has been taken seriously, and
METADAC’s study-facing committee members assess
each PLS according to guidance provided to applicants
[65]. As a reflection of the care by which PLSs are
reviewed, and to ensure data use is transparent to study
participants and the wider community, many applicants
are asked to improve their PLS. While guidance is read-
ily available, time-poor researchers do not always fully
absorb the instructions or do not recognise the import-
ance attached to PLSs by METADAC. The chief reason
applicants are asked to revise their applications is on the
basis of inadequate descriptions of their research.
Limitations
This ethnographic case study was informed by the evalu-
ation of the METADAC pilot. As such, it represents
findings at an interim stage of METADAC’s develop-
ment and should be read with this limitation in mind.
The ethnographic methods used here provide a deep
understanding of a phenomenon. Though they are not
statistically generalizable, the findings, as expected of
qualitative studies employing quality criteria for rigour
and trustworthiness, can be considered theoretically
generalizable to cognate settings.
Conclusions: future considerations for data and
samples access
At present, there is a strong strategic investment in en-
suring not only the optimisation of research data use,
but also of routine data generated by health and social
care services and other administrative data services.
Moving forward, the international research community
is proactively working towards creating a world in which
all such sources of data can, where beneficial, be inte-
grated, linked and jointly interpreted; this potential has
been demonstrated in the UK in projects such as The
Farr Institute, the Administrative Data Research Net-
work, Connected Health Cities, the pan-London Health
Information Exchange and the Medical Research
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Council’s Health Data Research UK initiative [3, 66–69].
The aims of such initiatives and the enhanced data util-
ity they provide are three-fold: (1) to better use data to
directly inform front-line clinical care and public health,
(2) to enhance the evidence base for health and social
care planning and strategic development and formally
evaluate key initiatives in these domains and (3) to en-
hance the quality and scope of research in health sci-
ence, bioscience and the social sciences. Given the
desirability of such aims and current investment by gov-
ernments and funders, it is inevitable that over the next
decade, DACs are going to have to deal with increasingly
large volumes of data generated from the health, social
care and other administrative data sources.
At least some DACs in the future are going to have to
be able to deal simultaneously, and effectively, with the
data access criteria they already apply to research data
and the laws, rules and regulations applicable, in the
UK, to National Health Service (NHS), social care and
administrative data (e.g. education, criminal records, na-
tional statistics). Whether research DACs evolve to deal
with NHS data (or as gatekeepers for NHS data), taking
account of the real risk of identification of at least some
individuals, even after pseudonymisation and similar
privacy-protecting mechanisms, will demand a profound
change in perspective. In addition, governing these data
will create a substantive additional workload and a need
to rapidly explore and develop appropriate systems
shortcuts and technological solutions to some aspects of
the assessment. Empirical evidence demonstrates that
DACs face serious challenges when a new class of data
suddenly becomes available: part of the argument for
creating METADAC was that a predecessor DAC was
not set up and therefore not able to deal effectively with
newly available genomic data. METADAC and several
studies under it have had to work hard (and rapidly) to
modify the systems and structures for releasing conven-
tional SNP-based genome-wide association data to deal
with full DNA sequence data and with methylation
data—even though many of the principles are unaltered.
Other studies, not part of METADAC, have invested ex-
tensive time in considering how—if at all—to manage
and govern new data classes such as data generated via
social media or image data.
The evolution of DACs that can deal jointly and effect-
ively with all of the criteria and rules applying to rou-
tinely collected health, social care or administrative data
and all of those already applied in dealing with research
data will be an equivalent challenge but of a much
higher order. This will particularly prove to be the case
when DACs have to start considering data generated
and interpreted in real time; indeed, many new applica-
tions of health data in the future will require that re-
search data from individuals can be combined with real-
time health service data to enable rapid clinical re-
sponses for diagnosis or management. If both the re-
search community and health and social care services
are to be ready when the new data start flowing, there is
a need for experts across all the domains and disciplines
relating to data access and sharing, including study
participants and users of health, social care and other
services, to have worked through all of these issues.
Human-mediated decision-making bodies will undoubt-
edly be central to ensuring the trustworthiness of the
most sensitive of those data, and achievable, reasoned
and responsible decisions about their use. The META-
DAC model we describe here provides a template for
such future governance.
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